Skip to main content

 Scientific publications

A rare case of prostatic extra gonadal germ cell tumor in a young adult: Review of the literature

Authors : Sideris S, Aftimos P, Georgala A, Sirtaine N, Awada A, Gil T
Year : 2014
Journal : J Clin Diagn Res
Volume : 2
Pages : 2

Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium.

Authors : Cornelis N, Vermassen T, Schallier D, Machiels JP, Gil T, Debruyne PR, DHondt R, Bols A, Schrijvers D, Mebis J, Lumen N, Rottey S
Year : 2014
Journal : Acta Clin Belg
Volume : 69(5)
Pages : 335-40

A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting av integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy.

Authors : Wirth M, Heidenreich A, Gschwend JE, Gil T, Zastrow S, Laniado M, Gerloff J, Zühlsdorf M, Mordenti G, Uhl W, Lannert H
Year : 2014
Journal : Eur Urol
Volume : 65(5)
Pages : 897-904

Autoimmune haemolytic anaemia in a patient treated with capecitabine.

Authors : Sideris S, Loizidou A, Georgala A, Lebrun F, Gil T, Awada A, Piccart-Gebhart M, Cardoso F
Year : 2013
Journal : Acta Clin Belg
Volume : 68(2)
Pages : 135-7

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Authors : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pages : 3219-28

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors : Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M
Year : 2013
Journal : Lancet Oncol
Volume : 14(8)
Pages : 760-8

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Authors : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Year : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Authors : Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G
Year : 2012
Journal : Eur. J. Cancer
Volume : 48(2)
Pages : 179-86

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

Authors : De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R
Year : 2012
Journal : J. Clin. Oncol.
Volume : 30(2)
Pages : 191-9

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Authors : Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Gebhart M, Hendlisz A
Year : 2011
Journal : J Clin Pharmacol
Volume : 51(12)
Pages : 1674-84

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.

Authors : Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F
Year : 2011
Journal : BJU Int
Volume : 108(5)
Pages : 679-686

mTor inhibition in RCC: proof of concept, clinical use, and future directions,

Authors : Aftimos P, Awada A, Gil T
Year : 2011
Journal : Belgian J Medical Oncology
Volume : 5(5)
Pages : 205-11